Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global In Vivo CRO Market Size, Share & Trends: 2019 to 2026 - ResearchAndMarkets.com

April 11, 2019

DUBLIN--(BUSINESS WIRE)--Apr 11, 2019--The “In vivo CRO Market Size, Share & Trends Analysis Report By Product Type, By GLP Type, By Indication (Diabetes, Obesity, Autoimmune/Inflammatory, CNS Conditions), And Segment Forecasts, 2019 - 2026” report has been added to ResearchAndMarkets.com’s offering.

The global in vivo CRO market is anticipated to reach USD 5.81 billion by 2026, according to this report. It is expected to expand at a CAGR of 8.5% during the forecast period.

Increasing focus on core competencies by the pharmaceutical players coupled with economic efficiency offered for outsourcing is expected to boost the demand.

In Addition, the CROs are equipped with a competent workforce capable of performing a diverse number of tasks along with being well-versed through regulatory requirements. Also, the pressure from the increasing competition owing to rapid growth of generics, patent expirations, and introduction of biosimilar equivalents are encouraging pharmaceutical companies to take the aid of such organizations.

Increasing mergers and collaborations have propelled the value of pharmaceutical outsourcing with major industry contributors expanding into developing regions. The year 2015 experienced high valued transactions as a result of LabCorp acquiring Covance for USD 5.5 billion and the Chinese Private Equity Group acquiring WuXi for USD 3.3 billion. The patent cliff, high research and development cost involved, and globalization in the clinical trial process has driven the

Further key findings from the report suggest:

  • Rodent based In vivo CRO led the market in 2018 and is anticipated to remain dominant throughout the forecast period. Mice is the most used animal for preclinical evaluation and accounted for almost 76% of the market share in 2018
  • Based on indication, oncology held the largest market share in 2018, attributed to the increasing number of cancer cases and focus of pharmaceutical players on introducing novel drug treatments with fewer side-effects
  • North America led the global In vivo CRO market in 2018 owing to the presence of technologically advanced CROs
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period. Constantly improving healthcare infrastructure, huge patient base, presence of untapped opportunities, and economic development, are some factors responsible for the rapid growth
  • Some of the key market players include Pharmaceutical Product Development, LLC (PPD); IQVIA; American Preclinical Services, LLC.; Charles River Laboratories; Parexel International Corporation; ICON Plc; Covance Inc.; Theorem Clinical research; inVentiv Health; WuXi AppTec, Inc.; American Preclinical Services, LLC.; and Evotec (US), Inc. Partnership and mergers and acquisitions are the key strategic undertakings by these players

Companies Mentioned

  • Quintiles
  • Charles River Laboratories
  • Icon PLC
  • Covance Inc.
  • Parexel International
  • Pharmaceutical Product Development
  • Theorem Clinical Research
  • Inventiv Health
  • Wuxi Apptec Inc.
  • American Preclinical Services
  • Evotec (US) Inc.

Key Topics Covered

Chapter 1 Report Scope

1.1 Segment Market Scope

1.2 Regional Scope

Chapter 2 Methodology

2.1 Research Methodology

2.2 Information Or Data Analysis

2.3 Market Formulation & Validation

2.4 Region Wise Market Calculation

2.5 Region Based Segment Share Calculation

2.6 Model Details

2.7 List Of Secondary Sources

2.8 List Of Primary Sources

2.9 List Of Abbreviations

Chapter 3 Objectives

3.1 Objective - 1:

3.2 Objective - 2:

3.3 Objective - 3:

3.4 Objective - 4:

Chapter 4 Executive Summary

4.1 Market Outlook

4.2 Segment Outlook

4.3 Competitive Insights

Chapter 5 In Vivo CRO Market: Variables, Trends & Scope

5.1 Market Lineage Outlook

5.2 Penetration & Growth Prospect Mapping

5.3 Product Pipeline Analysis, By Stage

5.4 User Perspective Analysis

5.5 List Of Key End-Users, By Region / By Product / By Country

5.6 Regulatory Framework

5.7 Market Variable Analysis

5.8 In Vivo CRO Market: Analysis Tools

Chapter 6 In Vivo CRO Market: Services Segment Analysis

6.1 In Vivo CRO Market: Definition & Scope

6.2 In Vivo CRO Market: Segment Dashboard

6.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

6.4 Rodent Based In Vivo GLP Type

6.5 Non-Rodent Based In Vivo GLP Type

Chapter 7 In Vivo CRO Market: Type Segment Analysis

7.1 In Vivo CRO Market: Definition & Scope

7.2 In Vivo CRO Market: Segment Dashboard

7.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

7.4 Non GLP

7.5 GLP Toxicology

Chapter 8 In Vivo CRO Market: Indication Segment Analysis

8.1 In Vivo CRO Market: Definition & Scope

8.2 In Vivo CRO Market: Segment Dashboard

8.3 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

8.4 Autoimmune/ Inflammatory Conditions

8.5 Pain Management

8.6 Oncology

8.7 CNS Conditions

8.8 Diabetes

8.9 Obesity

8.10 Others

Chapter 9 In Vivo CRO Market: Regional Analysis

9.1 In Vivo CRO Market: Definition & Scope

9.2 Regional Market Snapshot

9.3 Regional Market Share And Leading Players, 2018

9.4 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)

9.5 In Vivo CRO Market: Market Share Analysis, 2018 & 2026

9.6 North America

9.7 Europe

9.8 Asia Pacific

9.9 Latin America

9.10 MEA

Chapter 10 Competitive Analysis

10.1 Recent Developments & Impact Analysis, By Key Market Participants

10.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)

10.3 Vendor Landscape

10.4 Public Companies

10.5 Private Companies

10.6 Supplier Ranking

Chapter 11 Company Profiles

11.1 Strategic Framework

Chapter 12 KOL Commentary

Chapter 13 Recommendation

For more information about this report visit https://www.researchandmarkets.com/r/dfzio7

View source version on businesswire.com:https://www.businesswire.com/news/home/20190411005326/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/11/2019 05:56 AM/DISC: 04/11/2019 05:55 AM